breast-cancer-research.com

Table 2
Circulating levels of oestradiol, follicle-stimulating hormone and luteinizing hormone at baseline and after 12 months, and change from baseline to 12 months by treatment group
	Isoflavone group (n= 56)			Placebo (n = 61)^a

	Baseline	12 months	Change	Baseline	12 months	Change	P for change^b

Oestradiol (pmol/l)	22.6 ± 12.2	36.6 ± 65.0	14.0 ± 64.7	22.6 ± 13.3	21.6 ± 9.0	-0.9 ± 11.5	0.49
FSH (IU/l)	76.2 ± 21.5	72.0 ± 23.5	-4.2 ± 12.9	77.6 ± 25.1	74.5 ± 23.9	-2.9 ± 13.0	0.83
LH (IU/l)	43.9 ± 15.4	39.9 ± 14.6	-4.0 ± 11.7	45.5 ± 16.0	41.2 ± 12.0	-4.2 ± 9.2	0.71

Values are expressed as means ± standard deviation. ^aFor change in FSH, n = 60. ^bP value for difference between treatment groups for change. FSH, follicle-stimulating hormone; LH, luteinizing hormone.
Atkinson et al. Breast Cancer Res 2004 6:R170

Table 2